The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy
[ X ]
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Ediciones Doyma, S.L.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Objective: This study aimed to determine the prognostic role of baseline maximum standardized uptake value (SUVmax) obtained by pretreatment PET/CT and the change in SUVmax (?SUVmax [%]) in patients with axillary lymph node–positive breast cancer receiving neoadjuvant chemotherapy (NAC). Methods: One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAI) and the change in the SUVmax of the breast (?SUVmaxB) and axilla (?SUVmaxA) were measured. The optimal cut-off value of SUVmax and ?SUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan–Meier curves. Results: ?SUVmaxB, pCRB, pCRA, and pCR parameters were found to be associated with relapse (p < 0.001, p = 0.033, p = 0.016, and p = 0.013, respectively). ?SUVmaxB and SUVmaxAI were associated with mortality (p = 0.001 and p = 0.006, respectively). Multiple Cox regression analyses revealed that ?SUVmaxB value was an independent prognostic factor for relapse and mortality (p = 0.013 and p = 0.010, respectively). Conclusion: The results showed that ?SUVmaxB was an independent prognostic factor for relapse and mortality in patients with axillary lymph node–positive breast cancer who received NAC.
Açıklama
Anahtar Kelimeler
Breast cancer, Fdg Pet/Ct, Neoadjuvant chemotherapy, Prediction response, Prognosis, Suvmax change
Kaynak
Revista Espanola de Medicina Nuclear e Imagen Molecular
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
41
Sayı
1
Künye
Can, C., Akdeniz, N., Kömek, H., Gündogan, C., Urakçı, Z. ve Işıkdoǧan, A. (2022). The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy. Revista Espanola de Medicina Nuclear e Imagen Molecular, 41(1), 3-10.
